Ocugen, Inc. (NASDAQ:OCGN) Shares Bought by SG Americas Securities LLC

SG Americas Securities LLC grew its stake in shares of Ocugen, Inc. (NASDAQ:OCGN) by 72.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 152,176 shares of the company’s stock after acquiring an additional 64,080 shares during the quarter. SG Americas Securities LLC owned about 0.05% of Ocugen worth $123,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. MetLife Investment Management LLC increased its position in Ocugen by 36.4% during the 3rd quarter. MetLife Investment Management LLC now owns 89,508 shares of the company’s stock worth $89,000 after purchasing an additional 23,877 shares in the last quarter. NorthCrest Asset Manangement LLC acquired a new stake in Ocugen during the 3rd quarter worth approximately $90,000. Intech Investment Management LLC acquired a new stake in Ocugen during the 3rd quarter worth approximately $93,000. The Manufacturers Life Insurance Company acquired a new stake in Ocugen during the 2nd quarter worth approximately $166,000. Finally, Franklin Resources Inc. acquired a new stake in Ocugen during the 3rd quarter worth approximately $142,000. Institutional investors and hedge funds own 10.27% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. Maxim Group assumed coverage on shares of Ocugen in a research report on Tuesday, October 15th. They set a “buy” rating and a $4.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of Ocugen in a research report on Monday, January 13th. Finally, Chardan Capital restated a “buy” rating and issued a $6.00 price target on shares of Ocugen in a report on Thursday, January 23rd.

Ocugen Stock Down 4.0 %

NASDAQ OCGN opened at $0.67 on Wednesday. The stock has a market cap of $195.80 million, a PE ratio of -3.73 and a beta of 3.82. Ocugen, Inc. has a fifty-two week low of $0.55 and a fifty-two week high of $2.11. The business has a 50 day moving average price of $0.79 and a two-hundred day moving average price of $0.99. The company has a quick ratio of 2.58, a current ratio of 2.58 and a debt-to-equity ratio of 0.04.

Ocugen Company Profile

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.